



**L'ORÉAL AND SYMATESE STRENGTHEN THEIR STRATEGIC RESEARCH PARTNERSHIP
ON BIOMATERIALS**

Clichy / Lyon, 28 October 2021 – L'Oréal and Symatase have announced the signing of new long-term research and development agreements in the field of biomaterials, to strengthen and broaden their existing strategic partnership. Together, the companies aspire to combine their respective expertise to explore new scientific perspectives in the field of biomaterials designed for the physiology of human tissues including skin, notably for regeneration purposes.

This research partnership builds on the success of the close collaboration between the two companies during the past 20 years. Episkin S.A., a subsidiary of the L'Oréal group, the world leader in the production of reconstructed human tissues, has benefitted from the know-how developed historically with Symatase, a company recognized for the quality of its technological platforms to extract and transform biopolymers for multiple therapeutic indications. These reconstructed tissues have become a reference in the field of biomedical research, and a key tool for a number of industries as reliable non-animal evaluation methods for ingredient and product testing.

"Following our long-term collaboration with Symatase, we are very pleased to enter into this new phase of our scientific partnership, which supports the exploration of new horizons for research and innovation, with the objective to offer men and women around the world even more superior product performance with our beauty and skincare offering. Through this collaboration and thanks to Symatase's expertise in the therapeutic field, L'Oréal will benefit from an internationally recognized cutting-edge know-how in the field of biomaterials," said **Barbara Lavernos, Deputy CEO in charge of Research, Innovation and Technology, L'Oréal Group.**

Jean-Paul Gérardin, CEO of Symatase Group, said: *"We are delighted to establish this new partnership with L'Oréal, whose extensive expertise in the field of skin physiology, clinical performance markers and alternative assessment methods perfectly matches our knowledge in the design and industrialization of biomaterials. We expect great scientific advances and innovative products from this collaboration."*

About Symatase

Founded 24 years ago, Symatase Group employs 350 people. Every year, its innovative medical devices, combined with their delivery systems, are used by specialized practitioners, and make it possible to treat more than 20 Million patients worldwide per year. These products are created, developed, and manufactured within its 4 entities that operate its various technological platforms including tissue reconstruction and regeneration, inspired by nature, for various specialties, mostly surgical: plastic, reconstructive and aesthetic, cardiac and vascular, ophthalmic, orthopedic and rheumatological, dental and maxillofacial.
For more information: <https://www.symatase.com>

About L'Oréal

L'Oréal has devoted itself to beauty for over 100 years. With its unique international portfolio of 35 diverse and complementary brands, the Group generated sales amounting to 27.99 billion euros in 2020 and employs 85,400 people worldwide. As the world's leading beauty company, L'Oréal is present across all distribution networks: mass market, department stores, pharmacies and drugstores, hair salons, travel retail, branded retail and e-commerce.
Research and innovation with a dedicated research team of 4,000 people, are at the core of L'Oréal's strategy, working to meet beauty aspirations all over the world. L'Oréal sets out ambitious sustainable development goals across the Group for 2030 and aims to empower its ecosystem for a more inclusive and sustainable society.
More information on <https://www.loreal.com/en/mediaroom>

"This press release does not constitute an offer of sale or solicitation of an offer to purchase L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers, also available in English on our website www.loreal-finance.com.

This press release may contain forecast information. While the Company believes that these statements are based on reasonable assumptions as of the date of publication of this press release, they are by nature subject to risks and uncertainties which may lead to a discrepancy between the actual figures and those indicated or suggested in these statements."

CONTACTS L'ORÉAL

Switchboard
+33 (0)1 47 56 70 00

Individual shareholders and market regulators

Christian MUNICH
+33 (0)1 47 56 72 06
Christian.munich2@loreal.com

Financial analysts and institutional investors

Françoise LAUVIN
+33 (0)1 47 56 86 82
Francoise.lauvin@loreal.com

Media

Noëlle CAMILLERI
+33 (0)6 79 92 99 39
Noelle.camilleri@loreal.com

Christine BURKE
+33 (0)6 75 54 38 15
Christine.burke@loreal.com

CONTACTS SYMATESE

Business Development

Laurent Brones
l.brones@symatese.com

Médias

Patricia Bénitah
+33 (0)6 29 44 83 09
pbcom@pbcommunication.fr

For further information, please contact your bank, stockbroker or financial institution (I.S.I.N. code: FR000012031) and consult your usual newspapers or magazines or the Internet site for shareholders and investors, www.loreal-finance.com, the L'Oréal Finance app or call the toll-free number from France: 0 800 66 66 66. 0 800 66 66 66

 Follow us on Twitter @loreal
www.loreal.com

www.symatese.com